Rigorous results on superconducting ground states for attractive extended Hubbard models

We show that the exact ground state for a class of extended Hubbard models including bond-charge, exchange, and pair-hopping terms, is the Yang "eta-paired" state for any non-vanishing value of the pair-hopping amplitude, at least when the on-site Coulomb interaction is attractive enough and the remaining physical parameters satisfy a single constraint. The ground state is thus rigorously superconducting. Our result holds on a bipartite lattice in any dimension, at any band filling, and for arbitrary electron hopping.Comment: 12 page

A change in inflammatory foot print precedes plaque instability: A systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis

Transplant surger

Duality Twists, Orbifolds, and Fluxes

We investigate compactifications with duality twists and their relation to orbifolds and compactifications with fluxes. Inequivalent compactifications are classified by conjugacy classes of the U-duality group and result in gauged supergravities in lower dimensions with nontrivial Scherk-Schwarz potentials on the moduli space. For certain twists, this mechanism is equivalent to introducing internal fluxes but is more general and can be used to stabilize some of the moduli. We show that the potential has stable minima with zero energy precisely at the fixed points of the twist group. In string theory, when the twist belongs to the T-duality group, the theory at the minimum has an exact CFT description as an orbifold. We also discuss more general twists by nonperturbative U-duality transformations.Comment: 30 pages, harvmac, references and brief comments on gauged supergravity adde

Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors

Background:Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens.Methods:In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses.Results:After a median follow-up of 2

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

BackgroundPatients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were mostly excluded from clinical trials but potentially derive less benefit from immune checkpoint inhibitors (ICIs) due to disease- or treatment-related T- or B-cell dysfunction.MethodsAll advanced melanoma patients treated with anti-PD-1-based treatment or targeted therapy between 2015 and 2021 were included from the prospective nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS) and melanoma-specific survival (MSS) were analysed for patients with HM (HM+) and without HM (HM−). A cox model was used to account for confounders associated with PFS and MSS.ResultsIn total, 4638 advanced melanoma patients received first-line anti-PD-1 monotherapy (n = 1763), ipilimumab-nivolumab (n = 800), or BRAF(/MEK) inhibitors (n = 2075). Concurrent HMs were present for 46 anti-PD1-treated patients, 11 ipilimumab-nivolumab-treated patients and 43 BRAF(/MEK)-inhibitor-treated patients. In anti-PD-1-treated patients, the median PFS was 2.8 months for HM+ and 9.9 months for HM− (p = 0.01). MSS was 41.2 months for HM+ and 58.1 months for HM− (p = 0.00086). In multivariable analysis, the presence of an HM was significantly associated with higher risk of melanoma progression (HRadj 1.62; 95% confidence interval [95% CI] 1.15–2.29; p = 0.006) and melanoma-related death (HRadj 1.74; 95% CI 1.09–2.78; p = 0.020). Median PFS and MSS for first-line BRAF(/MEK-) inhibitor-treated HM+ and HM− patients were not significantly different.ConclusionsPatients with HM and advanced melanoma show significantly worse melanoma-related outcomes when treated with ICI, but not targeted therapy, compared to patients without HM. Clinicians should be aware of potentially altered effectiveness of ICI in patients with active HM.Analysis and support of clinical decision makin